Methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof
View Patent ↗Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions comprising prodrugs of methyl hydrogen fumarate, and methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof for treating diseases such as psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, and arthritis are disclosed.
1. A method of treating a patient suffering from a disease selected from psoriasis, multiple sclerosis, Huntington's disease, asthma, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease, rheumatoid arthritis, Crohn's disease, ankylosing spondylitis, ulcerative colitis and psoriatic arthritis, comprising administering to a patient in need thereof a compound of Formula (I) or a pharmaceutically acceptable salt thereof:
wherein:
R 1 and R 2 are independently chosen from hydrogen, C 1-6 alkyl, and substituted C 1-6 alkyl;
R 3 and R 4 are independently chosen from hydrogen, C 1-6 alkyl, substituted C 1-6 alkyl, C 1-6 heteroalkyl, substituted C 1-6 heteroalkyl, C 4-12 cycloalkylalkyl, substituted C 4-12 cycloalkylalkyl, C 7-12 arylalkyl, and substituted C 7-12 arylalkyl; or R 3 and R 4 together with the nitrogen to which they are bonded form a ring chosen from a C 5-10 heteroaryl, substituted C 5-10 heteroaryl, C 5-10 heterocycloalkyl, and substituted C 5-10 heterocycloalkyl; and
R 5 is methyl;
wherein each substituent group is independently chosen from halogen, —OH, —CN, —CF 3 , ═O, —NO 2 , benzyl, —C(O)NR 11 2 , —R 11 , —OR 11 , —C(O)R 11 , —COOR 11 , and —NR 11 2 wherein each R 11 is independently chosen from hydrogen and C 1-4 alkyl.
2. The method of claim 1 wherein the disease is selected from psoriasis and multiple sclerosis.
3. The method of claim 1 wherein the disease is psoriasis.
4. The method of claim 1 comprising administering a second therapeutic agent effective in treating psoriasis.
5. The method of claim 1 wherein the disease is multiple sclerosis.
6. The method of claim 1 comprising administering a second therapeutic agent effective in treating multiple sclerosis.
7. The method of claim 1 wherein the disease is selected from Huntington's disease, asthma, Parkinson's disease, amyotrophic lateral sclerosis, and Alzheimer's disease.
8. The method of claim 1 wherein the disease is selected from rheumatoid arthritis and Crohn's disease.
9. The method of claim 1 wherein the disease is selected from ankylosing spondylitis and ulcerative colitis.
10. The method of claim 1 , wherein each of R 1 and R 2 is hydrogen.
11. The method of claim 1 , wherein one of R 1 and R 2 is hydrogen and the other of R 1 and R 2 is chosen from methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, and sec-butyl.
12. The method of claim 1 , wherein R 3 and R 4 are independently chosen from hydrogen and C 1-6 alkyl.
13. The method of claim 1 , wherein R 3 and R 4 together with the nitrogen to which they are bonded form a C 5-10 heterocycloalkyl ring.
14. The method of claim 1 , wherein one of R 1 and R 2 is hydrogen and the other of R 1 and R 2 is chosen from hydrogen and C 1-6 alkyl; and R 3 and R 4 together with the nitrogen to which they are bonded form a ring chosen from morpholine, piperazine, and N-substituted piperazine.
15. The method of claim 1 , wherein one of R 1 and R 2 is hydrogen; and the other of R 1 and R 2 is chosen from hydrogen and C 1-6 alkyl; R 3 is hydrogen; and R 4 is chosen from hydrogen, C 1-6 alkyl, and benzyl.
16. The method of claim 1 , wherein the compound is chosen from:
(N,N-diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate;
methyl [N-benzylcarbamoyl]methyl (2E)but-2-ene-1,4-dioate;
methyl 2-morpholin-4-yl-2-oxoethyl (2E)but-2-ene-1,4-dioate;
(N-butylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate;
[N-(2-methoxyethyl)carbamoyl]methyl methyl (2E)but-2-ene-1,4-dioate;
2-{2-[(2E)-3-(methoxycarbonyl)prop-2-enoyloxy]acetylamino}acetic acid;
4-{2-[(2E)-3-(methoxycarbonyl)prop-2-enoyloxy]acetylamino}butanoic acid;
(N,N-dimethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate;
bis-(2-methoxyethylamino)carbamoyl]methyl methyl (2E)but-2-ene-1,4-dioate;
[N-(methoxycarbonyl)carbamoyl]methyl methyl (2E)but-2ene-1,4-dioate;
methyl 2-oxo-2-piperazinylethyl (2E)but-2-ene-1,4-dioate;
methyl 2-oxo-2-(2-oxo(1,3-oxazolidin-3-yl)ethyl (2E)but-2ene-1,4-dioate;
{N-[2-(dimethylamino)ethyl]carbamoyl}methyl methyl (2E)but-2ene-1,4 dioate;
methyl 2-(4-methylpiperazinyl)-2-oxoethyl (2E)but-2-ene-1,4-dioate;
methyl {N-[(propylamino)carbonyl]carbamoyl}methyl (2E)but-2ene-1,4-dioate;
2-(4-acetylpiperazinyl)-2-oxoethyl methyl (2E)but-2ene-1,4-dioate;
{N,N-bis[2-(methylethoxy)ethyl]carbamoyl}methyl methyl (2E)but-2-ene-1,4-dioate;
methyl 2-(4-benzylpiperazinyl)-2-oxoethyl (2E)but-2-ene-1,4-dioate;
[N,N-bis(2-ethoxyethyl)carbamoyl]methyl methyl (2E)but-2-ene-1,4-dioate;
2-{(2S)-2-[tert-butyl)oxycarbonyl]pyrrolidinyl}-2-oxoethyl methyl (2E)but-2ene-1,4-dioate;
1-{2-{(2E)-3-(methoxycarbonyl)prop-2-enoyloxy]acetyl}(2S)pyrrolidine-2-carboxylic acid;
(N-{[tert-butyl)oxycarbonyl]methyl}-N-methylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate;
{N-(ethoxycarbonyl)methyl]-N-methylcarbamoyl}methyl methyl (2E)but-2-ene-1,4-dioate;
methyl 1-methyl-2-morpholin-4-yl-2-oxoethyl(2E)but-2-ene-1,4-dioate;
[N,N-bis(2-methoxyethyl)carbamoyl]ethyl methyl (2E)but-2-ene-1,4-dioate;
(N,N-dimethylcarbamoyl)ethyl methyl (2E)but-2-ene-1,4-dioate;
2-{2-[(2E)-3-(methoxy carbonyl)prop-2-enoyloxyl]-N-methylacetylamino}acetic acid;
(N-{[(tert-butyl)oxycarbonyl]methyl}carbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate;
methyl (N-methyl-N-{[(methylethyl)oxycarbonyl]methyl}carbamoyl)methyl (2E)but-2-ene-1,4-dioate;
{N-[(ethoxycarbonyl)methyl]-N-benzylcarbamoyl}methyl methyl (2E)but-2-ene-1,4-dioate;
{N-[(ethoxycarbonyl)methyl]-N-benzylcarbamoyl}ethyl methyl (2E)but-2-ene-1,4-dioate;
{N-[(ethoxycarbonyl)methyl]-N-methylcarbamoyl}ethyl methyl (2E)but-2-ene-1,4-dioate;
(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl methyl (2E)but-2-ene-1,4-dioate;
(1S)-1-[N,N-bis(2-methoxyethyl)carbamoyl]ethyl methyl (2E)but-2-ene-1,4-dioate;
(1R)-1-(N,N-diethylcarbamoyl)ethyl methyl (2E)but-2-ene-1,4-dioate;
(N-[(methoxycarbonyl)ethyl]carbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate;
2-{2-[(2E)-3-(methoxycarbonyl)prop-2-enoyloxy]acetylamino}propanoic acid; and
pharmaceutically acceptable salts of any of the foregoing.
17. The method of claim 1 , wherein R 3 and R 4 are independently chosen from methyl, ethyl, methoxyethyl; or R 3 and R 4 together with the nitrogen to which they are bonded form a 4-morpholinyl group.
18. The method of claim 1 , wherein the compound is (N,N-diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate.
19. The method of claim 18 , wherein the disease is psoriasis.
20. The method of claim 18 , wherein the disease is multiple sclerosis.
21. The method of claim 18 , wherein the compound is in an oral formulation.
22. The method of claim 21 , wherein the oral formulation is an oral sustained release formulation.
23. The method of claim 1 , wherein the compound is methyl 2-morpholin-4-yl-2-oxoethyl (2E)but-2-ene-1,4-dioate.
24. The method of claim 23 , wherein the disease is psoriasis.
25. The method of claim 23 , wherein the disease is multiple sclerosis.
26. The method of claim 23 , wherein the compound is in an oral formulation.
27. The method of claim 23 , wherein the oral formulation is an oral sustained release formulation.
28. The method of claim 1 , wherein the compound is bis-(2-methoxyethylamino)carbamoyl]methyl methyl (2E)but-2-ene-1,4-dioate.
29. The method of claim 28 , wherein the disease is psoriasis.
30. The method of claim 28 , wherein the disease is multiple sclerosis.
31. The method of claim 28 , wherein the compound is in an oral formulation.
32. The method of claim 31 , wherein the oral formulation is an oral sustained release formulation.
33. The method of claim 1 , wherein the compound is (N,N-dimethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate.
34. The method of claim 33 , wherein the disease is psoriasis.
35. The method of claim 33 , wherein the disease is multiple sclerosis.
36. The method of claim 33 , wherein the compound is in an oral formulation.
37. The method of claim 36 , wherein the oral formulation is an oral sustained release formulation.
38. The method of claim 1 wherein the compound is in an oral formulation.
39. The method of claim 38 wherein the oral formulation is an oral sustained release formulation.
40. The method of claim 1 comprising administering a second therapeutic agent effective in minimizing an adverse effect associated with the compound of Formula (I).
41. The method of claim 1 comprising administering a second therapeutic agent selected from a non-steroidal anti-inflammatory agent and a cox-2 inhibitor.
42. The method of claim 1 comprising administering a second therapeutic agent selected from vitamin E, paroxetine, gabapentin and pentoxifylline.